{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/malaria-prophylaxis/prescribing-information/proguanil/","result":{"pageContext":{"chapter":{"id":"a6e70a24-4baa-514f-9d3a-a7ccb0d9b45c","slug":"proguanil","fullItemName":"Proguanil","depth":2,"htmlHeader":"<!-- begin field e3dd8226-af82-4f17-8ce4-7d2f0868c836 --><h2>Prescribing proguanil</h2><!-- end field e3dd8226-af82-4f17-8ce4-7d2f0868c836 -->","summary":"","htmlStringContent":"<!-- begin item 2a94cc6e-cede-4c52-95c9-b689e78d4192 --><!-- begin field 587cec01-cd42-45f7-bd4a-a88e00d43a57 --><ul><li><strong>Regimen</strong><ul><li>Proguanil is usually prescribed with chloroquine or atovaquone as a combination product.</li><li>Dosing schedule depends on whether proguanil is given alone or in combination:<ul><li>If given alone — proguanil is available in tablet form and usually taken daily, at the same time each day, starting one week before entering an endemic area, continuing throughout the time in the area and for 4 weeks after leaving the area.</li><li>When combined with chloroquine – dosing should start 1 week before entering the endemic and be continued until 4 weeks after leaving the area.</li><li>When combined with atovaquone — dosing should start 1 or 2 days before entering the endemic area and be continued until 1 week after leaving the area.</li></ul></li><li>Proguanil is considered safe for long-term use in malaria prophylaxis.</li><li>As proguanil is a folate inhibitor, folic acid (5 mg daily) supplementation should be taken by women who are pregnant or planning a pregnancy and taking proguanil.</li></ul></li><li><strong>Contraindications</strong><ul><li>Hypersensitivity to proguanil or to any ingredient of the tablets.</li></ul></li><li><strong>Cautions</strong><ul><li>Renal impairment — dose may need adjusted.</li><li>Pregnancy — folic acid 5 mg daily should be taken for at least the first trimester if proguanil is used in pregnancy or in women taking proguanil and planning pregnancy.</li></ul></li><li><strong>Interactions</strong><ul><li>May enhance the anticoagulant effect of warfarin.</li><li>Antifolate effect is increased when given with pyrimethamine.</li><li>Antacids may reduce the absorption of proguanil, so should be taken at least 2–3 hours apart.</li></ul></li><li><strong>Adverse effects</strong><ul><li><strong>Common or very common reported adverse effects include:</strong><ul><li>Mild gastrointestinal effects such as constipation, diarrhoea, and nausea.</li></ul></li><li><strong>Uncommon adverse effects include:</strong><ul><li>Cholestasis; hair loss; skin reactions; and vasculitis.</li><li>Mouth ulcers and stomatitis occur occasionally, particularly when taken with chloroquine.</li></ul></li></ul></li><li><strong>Children</strong><ul><li>Proguanil can be difficult to administer to children as it is only available in tablet form which (depending on the age of the child) may need to be powdered into food.</li></ul></li><li><strong>Pregnancy and breastfeeding</strong><ul><li>Limited data have not shown an increased risk of congenital malformation but as proguanil is a folate antagonist and there is a theoretical risk of congenital malformations associated with folate deficiency the UK Teratology Information Service (UKTIS) recommend that pregnant women take high dose folic acid (5 mg daily) in conjunction with proguanil.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">UKTIS, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>]</p><!-- end field 587cec01-cd42-45f7-bd4a-a88e00d43a57 --><!-- end item 2a94cc6e-cede-4c52-95c9-b689e78d4192 -->","topic":{"id":"1dfdf856-ced9-50bb-8739-9ac597e749da","topicId":"fcbcecf9-c37c-4236-a0f0-e6ea3ff72076","topicName":"Malaria prophylaxis","slug":"malaria-prophylaxis","lastRevised":"Last revised in January 2018","chapters":[{"id":"ce4f76aa-9527-5f8c-9846-98b8c95af6e4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6fd40a83-7b55-56f4-97de-93dd8ba2ad8f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"665f9f2c-5318-56d6-ac14-83dd936bdf97","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"62945b37-6310-5a07-b2dc-90e23836e367","slug":"changes","fullItemName":"Changes"},{"id":"57a7f2b1-f3c6-5c7c-be23-60a85ca3e97f","slug":"update","fullItemName":"Update"}]},{"id":"4cbf6005-cbd7-5792-be78-1e08b1755887","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"24cd959e-2b4a-53d8-9a67-2cb6351480d4","slug":"goals","fullItemName":"Goals"},{"id":"8bfd8f1f-5162-55f5-98d0-024aa470eda3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6e3197bd-4c7e-50e3-8571-464b20b486e6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"68b0fb84-1d6e-5755-9c2e-89fd57721afa","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0e6ae722-735b-5e79-85d2-194cb8187380","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"66ce78ae-da4a-51bf-9d51-ae896236d71d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f8048c7c-b171-5f3b-91f0-2a353065712f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0f3bc680-088f-5879-bf5b-9cc85a3ea0ff","slug":"definition","fullItemName":"Definition"},{"id":"b849c9ff-c93f-5656-a227-098952e12f88","slug":"causes","fullItemName":"Causes"},{"id":"caad75c1-ac57-5c45-b040-8526b6235302","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ef83916a-1184-5356-93ba-f9bac26e167a","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a763547a-e2f3-5435-b3e5-36b2b8ad0c9e","slug":"complications","fullItemName":"Complications"}]},{"id":"254e9708-01a9-5862-801a-70f9e1fb5e84","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3379892e-94c0-5840-a578-cb5766212c69","slug":"assessment","fullItemName":"Assessment"},{"id":"4f391cab-b5f3-563e-be8a-a7235fe6467f","slug":"clinical-features","fullItemName":"Clinical features"}]},{"id":"18712f50-06cc-5638-9851-5c50e65488b5","fullItemName":"Management","slug":"management","subChapters":[{"id":"97193dc0-631b-5bea-89f3-7e605df7f3f4","slug":"malaria-prevention-in-travellers-from-the-uk","fullItemName":"Scenario: Malaria prevention in travellers from the UK"}]},{"id":"7750a127-e87f-5079-8777-0c8f13536296","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d4c5d3cf-2088-5d0a-94a1-af0994185aa5","slug":"drug-availability-on-the-nhs","fullItemName":"Drug availability on the NHS"},{"id":"f0cf5bcc-8534-50cf-a520-0e80e777e72d","slug":"prescribing-in-children","fullItemName":"Prescribing in children"},{"id":"2f74fd56-68c0-56c8-a07c-22482e10e67e","slug":"chloroquine","fullItemName":"Chloroquine"},{"id":"a6e70a24-4baa-514f-9d3a-a7ccb0d9b45c","slug":"proguanil","fullItemName":"Proguanil"},{"id":"2ce163bd-7fa7-51bd-8554-3a6a1cafdfa1","slug":"mefloquine","fullItemName":"Mefloquine"},{"id":"4ca8c124-4f45-50ce-a3b2-9a02219d6ab9","slug":"proguanil-plus-atovaquone","fullItemName":"Proguanil plus atovaquone"},{"id":"57e80cdf-fc37-5774-979d-f58301a7b5fb","slug":"doxycycline","fullItemName":"Doxycycline"}]},{"id":"38b67274-c723-5e50-9cdd-5cc01de962cb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91d3306b-2734-52a0-ac13-1adf3711008a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bb5bc365-9c32-5684-9333-e464e129ad67","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7b7d36b2-37d8-5815-836a-898e104a533e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2d5b97c9-c3d7-51bf-beae-65128d39bd5d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d69ddbc4-81c8-5404-8a15-7bc2502831cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c2fc1581-dd5f-5317-a19f-cfb72905246e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d7b5a2b6-f6a2-529e-8337-1780d8941d2c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7750a127-e87f-5079-8777-0c8f13536296","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}